Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA OKs first generic drug to treat severe hypoglycemia

By Brian Buntz | December 31, 2020

FDA logoThe FDA has approved the first generic of glucagon for injection for severe hypoglycemia, which can afflict some patients with diabetes. 

FDA has also indicated glucagon to facilitate diagnosis in radiological exams of the digestive tract as the drug can reduce intestinal motility. 

Glucagon is a hormone that, when released, triggers the liver to release glucose rapidly.

Last year, the agency approved Eli Lilly’s (NYSE:LLY) Baqsimi nasal powder, the first glucagon therapy indicated for the emergency treatment of severe hypoglycemia that can be administered without an injection.

Glucagon for injection has been on the market in the U.S. for more than two decades. Until recently, however, “there has been no approved generic of this important drug that can save the lives of people who may experience the serious condition of very low blood sugar,” noted Sally Choe, director of the Office of Generic Drugs in FDA’s Center for Drug Evaluation and Research in a statement. 

Chloe noted that the FDA has been working to ramp up approvals of safe and effective drugs to help curb drug prices in the U.S. 

The agency maintains a list of off-patent, off-exclusivity drug products lacking approved generic equivalents.  

Tell Us What You Think! Cancel reply

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards